Soleil Boughton - 09 Feb 2024 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Legal Officer
Signature
/s/ Soleil Boughton
Issuer symbol
HIMS
Transactions as of
09 Feb 2024
Net transactions value
-$204,633
Form type
4
Filing time
13 Feb 2024, 19:27:28 UTC
Previous filing
03 Jan 2024
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Options Exercise $9,914 +4,080 +2.6% $2.43 158,425 09 Feb 2024 Direct F1
transaction HIMS Class A Common Stock Sale $40,921 -4,080 -2.6% $10.03 154,345 09 Feb 2024 Direct F1, F2
transaction HIMS Class A Common Stock Options Exercise $55,499 +22,839 +15% $2.43 177,184 12 Feb 2024 Direct F1
transaction HIMS Class A Common Stock Sale $229,125 -22,839 -13% $10.03 154,345 12 Feb 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise $0 -4,080 -1.8% $0.000000 223,310 09 Feb 2024 Class A Common Stock 4,080 $2.43 Direct F4
transaction HIMS Stock Option (right to buy) Options Exercise $0 -22,839 -10% $0.000000 200,471 12 Feb 2024 Class A Common Stock 22,839 $2.43 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercised and related sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2023 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $10.00 - $10.07. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $10.00 - $10.09. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 The option award vests over a four year period, with 1/48 of the shares subject to the stock option vesting when the Reporting Person completes each month of continuous Service beginning February 12, 2020.